O gravitomagnetskom satnom č

We show that the whole of the gravitomagnetic clock effect in the orbit of a spinning test particle which is revolving round a spinning central massive astrophysical body can be calculated using a gravitational spin-orbit coupling potential which involves the two spins and the orbital angular momentum of the test particle.Pokazujemo da se ukupni gravitomagnetski satni učinak za stazu ispitne čestice, koja se vrti i kruži oko središnjeg masivnog astrofizičkog tijela koje se vrti, može izračunati primjenom gravitacijskog potencijala vezanja spina i staze dviju vrtnji i staznog momenta impulsa ispitne čestice

Global patient outcomes after elective surgery: prospective cohort study in 27 low-, middle- and high-income countries.

BACKGROUND: As global initiatives increase patient access to surgical treatments, there remains a need to understand the adverse effects of surgery and define appropriate levels of perioperative care. METHODS: We designed a prospective international 7-day cohort study of outcomes following elective adult inpatient surgery in 27 countries. The primary outcome was in-hospital complications. Secondary outcomes were death following a complication (failure to rescue) and death in hospital. Process measures were admission to critical care immediately after surgery or to treat a complication and duration of hospital stay. A single definition of critical care was used for all countries. RESULTS: A total of 474 hospitals in 19 high-, 7 middle- and 1 low-income country were included in the primary analysis. Data included 44 814 patients with a median hospital stay of 4 (range 2-7) days. A total of 7508 patients (16.8%) developed one or more postoperative complication and 207 died (0.5%). The overall mortality among patients who developed complications was 2.8%. Mortality following complications ranged from 2.4% for pulmonary embolism to 43.9% for cardiac arrest. A total of 4360 (9.7%) patients were admitted to a critical care unit as routine immediately after surgery, of whom 2198 (50.4%) developed a complication, with 105 (2.4%) deaths. A total of 1233 patients (16.4%) were admitted to a critical care unit to treat complications, with 119 (9.7%) deaths. Despite lower baseline risk, outcomes were similar in low- and middle-income compared with high-income countries. CONCLUSIONS: Poor patient outcomes are common after inpatient surgery. Global initiatives to increase access to surgical treatments should also address the need for safe perioperative care. STUDY REGISTRATION: ISRCTN5181700

Optimisation of Perioperative Cardiovascular Management to Improve Surgical Outcome II (OPTIMISE II) trial: study protocol for a multicentre international trial of cardiac output-guided fluid therapy with low-dose inotrope infusion compared with usual care in patients undergoing major elective gastrointestinal surgery.

INTRODUCTION: Postoperative morbidity and mortality in older patients with comorbidities undergoing gastrointestinal surgery are a major burden on healthcare systems. Infections after surgery are common in such patients, prolonging hospitalisation and reducing postoperative short-term and long-term survival. Optimal management of perioperative intravenous fluids and inotropic drugs may reduce infection rates and improve outcomes from surgery. Previous small trials of cardiac-output-guided haemodynamic therapy algorithms suggested a modest reduction in postoperative morbidity. A large definitive trial is needed to confirm or refute this and inform widespread clinical practice. METHODS: The Optimisation of Perioperative Cardiovascular Management to Improve Surgical Outcome II (OPTIMISE II) trial is a multicentre, international, parallel group, open, randomised controlled trial. 2502 high-risk patients undergoing major elective gastrointestinal surgery will be randomly allocated in a 1:1 ratio using minimisation to minimally invasive cardiac output monitoring to guide protocolised administration of intravenous fluid combined with low-dose inotrope infusion, or usual care. The trial intervention will be carried out during and for 4 hours after surgery. The primary outcome is postoperative infection of Clavien-Dindo grade II or higher within 30 days of randomisation. Participants and those delivering the intervention will not be blinded to treatment allocation; however, outcome assessors will be blinded when feasible. Participant recruitment started in January 2017 and is scheduled to last 3 years, within 50 hospitals worldwide. ETHICS/DISSEMINATION: The OPTIMISE II trial has been approved by the UK National Research Ethics Service and has been approved by responsible ethics committees in all participating countries. The findings will be disseminated through publication in a widely accessible peer-reviewed scientific journal. TRIAL REGISTRATION NUMBER: ISRCTN39653756.The OPTIMISE II trial is supported by Edwards Lifesciences (Irvine, CA) and the UK National Institute for Health Research through RMP’s NIHR Professorship

Social media use in pre-trip planning by tourists visiting a small regional leisure destination

The aim of this study is to develop a better understanding of the use of social media in tourism pre-trip information search patterns for small regional leisure destinations. Only limited research has previously focused on how small regional destinations use and adopt social media strategies. This study addresses this gap in the literature by developing a better understanding of the challenges faced by small regional destinations. The results based on a visitor survey of 986 tourists found that social media was important for 27.9% of respondents when searching for information about their upcoming trip. Surprisingly, only a small number of respondents (15.6%) reported using apps to assist them make travel decisions. The growth in the use of social media allied with increasing ownership levels of smartphones indicates that destination marketing organizations of small regional destinations need to pay greater attention to social media and its delivery systems including smartphones. Implications are discussed for managers and stakeholders of small regional destinations, who may find this study valuable in guiding their future social media marketing efforts

THE USE OF BIOSENSORS IN DETERMINATION OF DIFFERENT SUBSTANCES BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY

A rapid, simple and economic method was developed, which combines the specificity of enzymes with the high sensitivity of HPLC. Therefore sample pretreatment is reduced to simple dilution or extraction steps. In this work oxidases for alcohol, glucose, oxalic acid, ascorbic acid and galactose were immobilized and used as biosensors. Food samples were fruit juices and vegetable products, soft drinks and wine. The detection limit e.g. for oxalic acid was in the picomol range

Development of an (<em>S</em>)-1-{2-[Tris(4-methoxyphenyl)methoxy]ethyl}piperidine-3-carboxylic acid [(<em>S</em>)-SNAP-5114] carba analogue inhibitor for murine &gamma;-aminobutyric acid transporter type&thinsp;4.

A series of GABA uptake inhibitors related to (S)-1-{2-[tris(4-methoxyphenyl)methoxy]ethyl}piperidine-3-carboxylic acid [(S)-SNAP-5114], the most potent mGAT4 inhibitor known so far, were synthesized and biologically evaluated for their inhibitory potency at the four GABA uptake transporters mGAT14 stably expressed in HEK-293 cell lines. New analogues were developed with potencies that are similar to or slightly higher than those of current mGAT4 inhibitors, but with distinctly improved chemical stability. (S)-Nipecotic acid derivatives possessing a 2-[1-(4-methoxy-2-methylphenyl)-1,1-bis(4-methoxyphenyl)methoxy]ethyl (DDPM-859) or a 4,4,4-tris(4-methoxyphenyl)but-2-en-1-yl moiety (DDPM-1457) were found to exhibit pIC50 values of 5.78 and 5.87, respectively. Thus, as mGAT4 inhibitors, these compounds compare well with (S)-SNAP-5114 (pIC50=5.71), but are far more stable than the latter. Moreover, DDPM-859 displays a more favorable subtype selectivity for mGAT4 versus mGAT3 than does (S)-SNAP-5114

Unraveling the effect of ZrO2 modifiers on the nature of active sites on AuRu/ZrO2 catalysts for furfural hydrogenation

Ru and AuRu nanoparticles were prepared by a sol-immobilization methodology and deposited on different doped zirconia supports (ZrO2, Y\u2013ZrO2 and La\u2013ZrO2). The catalysts were characterized by analytic transmission electron microscopy (TEM), Fourier transform infrared spectroscopy (FTIR) in a controlled atmosphere and X-ray photoelectron spectroscopy (XPS). TEM analysis showed that AuRu catalysts consist of Au\u2013Ru particle aggregates with small Ru particles enriched on the Au surface. FTIR experiments of adsorbed CO and XPS analyses revealed that the presence of gold modifies the electronic properties of Ru, confirming the bimetallic nature of AuRu nanoparticles. The catalysts were tested in furfural hydrogenation using isopropanol as the hydrogen donor. The addition of Au to Ru did not significantly modify the activity and selectivity but enhanced the resistance to deactivation. The acid\u2013base properties were monitored by acetonitrile adsorption followed by FTIR spectroscopy. It was shown that the acidity of the support greatly influences the selectivity. In particular, 71% selectivity to gamma-valerolactone was achieved over AuRu/Y\u2013ZrO2, due to the modified acidic strength of Zr4+ sites on the Y-doped oxide